{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69"},{"groupId":"OG001","value":"0.53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma","groups":[{"description":"Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.","id":"OG000","title":"EPOCH + Concurrent Rituximab"},{"description":"Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.","id":"OG001","title":"EPOCH Followed by Rituximab"}],"paramType":"NUMBER","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"60 days","title":"Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment","type":"PRIMARY","unitOfMeasure":"proportion"}